💨 Abstract

Eli Lilly announced that its experimental pill form of GLP-1 medications helped people with type 2 diabetes lose an average of 8% of their body weight after 40 weeks and lowered A1C levels. The pill, orforglipron, is the first of its kind to complete a Phase 3 trial, and no diet restrictions are needed. It reduced weight by 16 pounds among participants with inadequate glycemic control.

Courtesy: wtop.com

Summarized by Einstein Beta 🤖